Dr. Ivana Magovčević-Liebisch has served on Acrivon's Board since February 2024. She is President and CEO of Draig Therapeutics, a role she assumed after serving as President and CEO of Vigil Neuroscience until its acquisition by Sanofi in August 2025. She was previously Executive Vice President and Chief Business Officer at Ipsen from 2018 to 2020. She currently serves on the boards of Quanterix Corporation and Draig Therapeutics and was previously chairperson of the board of Absci and a director of Aeglea BioTherapeutics and Applied Genetic Technologies. She holds a Ph.D. in genetics from Harvard University, a J.D. from Suffolk University Law School and a B.A. in biology and chemistry from Wheaton College. She serves on Acrivon's Audit Committee.